Cargando…
Back to the future: recombinant polyclonal antibody therapeutics
Antibody therapeutics are one of the fastest growing classes of pharmaceuticals, with an annual US market over $20 billion, developed to treat a variety of diseases including cancer, auto-immune and infectious diseases. Most are currently administered as a single molecule to treat a single disease;...
Autores principales: | Wang, Xian-zhe, Coljee, Vincent W, Maynard, Jennifer A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892273/ https://www.ncbi.nlm.nih.gov/pubmed/24443710 http://dx.doi.org/10.1016/j.coche.2013.08.005 |
Ejemplares similares
-
Single-Batch Production of Recombinant Human Polyclonal Antibodies
por: Nielsen, Lars S., et al.
Publicado: (2010) -
Characterization of rabbit polyclonal antibody against camel recombinant nanobodies
por: Khalaf, Houssam-Eddin, et al.
Publicado: (2022) -
Investigation of Conditions for Capture of Live Legionella pneumophila with Polyclonal and Recombinant Antibodies
por: Paladines, Lucas, et al.
Publicado: (2022) -
Polyclonal antibodies against the recombinantly expressed coat protein of the Citrus psorosis virus
por: Salem, Reda, et al.
Publicado: (2018) -
From Polyclonal Sera to Recombinant Antibodies: A Review of Immunological Detection of Gluten in Foodstuff
por: Garcia-Calvo, Eduardo, et al.
Publicado: (2020)